XML 122 R97.htm IDEA: XBRL DOCUMENT
v3.20.4

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions | 12 Months Ended |  |
--- | --- | --- | ---
Jan. 03, 2021 | Dec. 29, 2019 | Dec. 30, 2018 | Oct. 31, 2020 | Oct. 31, 2019
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 82,584 | $ 82,059 | $ 81,581 |  |
Percentage Change In Sales By Segment Of Business | 0.60% | 0.60% |  |  |
Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 14,053 | $ 13,898 | 13,853 |  |
Percentage Change In Sales By Segment Of Business | 1.10% | 0.30% |  |  |
Pharmaceutical |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 45,572 | $ 42,198 | 40,734 |  |
Percentage Change In Sales By Segment Of Business | 8.00% | 3.60% |  |  |
Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 15,055 | $ 13,950 | 13,120 |  |
Percentage Change In Sales By Segment Of Business | 7.90% | 6.30% |  |  |
Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,574 | $ 3,413 | 3,304 |  |
Percentage Change In Sales By Segment Of Business | 4.70% | 3.30% |  |  |
Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 6,548 | $ 6,328 | 6,077 |  |
Percentage Change In Sales By Segment Of Business | 3.50% | 4.10% |  |  |
Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 12,367 | $ 10,692 | 9,844 |  |
Percentage Change In Sales By Segment Of Business | 15.70% | 8.60% |  |  |
Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,148 | $ 2,623 | 2,573 |  |
Percentage Change In Sales By Segment Of Business | 20.00% | 1.90% |  |  |
Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,878 | $ 5,192 | 5,816 |  |
Percentage Change In Sales By Segment Of Business | (6.00%) | (10.70%) |  |  |
Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 22,959 | $ 25,963 | 26,994 |  |
Percentage Change In Sales By Segment Of Business | (11.60%) | (3.80%) |  |  |
Medical Devices | Diabetes Care |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers |  |  | 1,009 |  |
Medical Devices | Interventional Solutions |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,046 | $ 2,997 | 2,646 |  |
Percentage Change In Sales By Segment Of Business | 1.60% | 13.30% |  |  |
Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 7,763 | $ 8,839 | 8,885 |  |
Percentage Change In Sales By Segment Of Business | (12.20%) | (0.50%) |  |  |
Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 8,232 | $ 9,501 | 9,901 |  |
Percentage Change In Sales By Segment Of Business | (13.40%) | (4.00%) |  |  |
Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,919 | $ 4,624 | 4,553 |  |
Percentage Change In Sales By Segment Of Business | (15.20%) | 1.60% |  |  |
Baby Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,517 | $ 1,675 | 1,858 |  |
Percentage Change In Sales By Segment Of Business | (9.40%) | (9.90%) |  |  |
Oral Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,641 | $ 1,528 | 1,555 |  |
Percentage Change In Sales By Segment Of Business | 7.40% | (1.70%) |  |  |
OTC | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,824 | $ 4,444 | 4,334 |  |
Percentage Change In Sales By Segment Of Business | 8.50% | 2.50% |  |  |
Women's Health | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 901 | $ 986 | 1,049 |  |
Percentage Change In Sales By Segment Of Business | (8.60%) | (6.00%) |  |  |
Wound Care and Other | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 720 | $ 671 | 675 |  |
Percentage Change In Sales By Segment Of Business | 7.20% | (0.60%) |  |  |
Remicade | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,747 | $ 4,380 | 5,326 |  |
Percentage Change In Sales By Segment Of Business | (14.40%) | (17.80%) |  |  |
Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,243 | $ 2,188 | 2,084 |  |
Percentage Change In Sales By Segment Of Business | 2.60% | 5.00% |  |  |
Stelara | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 7,707 | $ 6,361 | 5,156 |  |
Percentage Change In Sales By Segment Of Business | 21.10% | 23.40% |  |  |
Tremfya | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,347 | $ 1,012 | 544 |  |
Percentage Change In Sales By Segment Of Business | 33.20% | 85.90% |  |  |
Other Immunology | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 11 | $ 10 | 10 |  |
Percentage Change In Sales By Segment Of Business | 6.40% | 4.50% |  |  |
EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 964 | $ 861 | 816 |  |
Percentage Change In Sales By Segment Of Business | 11.90% | 5.60% |  |  |
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,184 | $ 2,110 | 1,955 |  |
Percentage Change In Sales By Segment Of Business | 3.50% | 8.00% |  |  |
Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 427 | $ 441 | 533 |  |
Percentage Change In Sales By Segment Of Business | (3.20%) | (17.30%) |  |  |
CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 622 | $ 696 | 663 |  |
Percentage Change In Sales By Segment Of Business | (10.60%) | 4.90% |  |  |
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,653 | $ 3,330 | 2,928 |  |
Percentage Change In Sales By Segment Of Business | 9.70% | 13.70% |  |  |
RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 642 | $ 688 | 737 |  |
Percentage Change In Sales By Segment Of Business | (6.80%) | (6.70%) |  |  |
OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,632 | $ 1,614 | 1,749 |  |
Percentage Change In Sales By Segment Of Business | 1.10% | (7.70%) |  |  |
DARZALEX | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,190 | $ 2,998 | 2,025 |  |
Percentage Change In Sales By Segment Of Business | 39.80% | 48.00% |  |  |
Erleada | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 760 | $ 332 | 124 |  |
IMBRUVICA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,128 | $ 3,411 | 2,615 |  |
Percentage Change In Sales By Segment Of Business | 21.00% | 30.40% |  |  |
VELCADE | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 408 | $ 751 | 1,116 |  |
Percentage Change In Sales By Segment Of Business | (45.70%) | (32.70%) |  |  |
ZYTIGA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,470 | $ 2,795 | 3,498 |  |
Percentage Change In Sales By Segment Of Business | (11.60%) | (20.10%) |  |  |
Other Oncology | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 413 | $ 407 | 466 |  |
Percentage Change In Sales By Segment Of Business | 1.70% | (12.70%) |  |  |
OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,639 | $ 1,327 | 1,215 |  |
Percentage Change In Sales By Segment Of Business | 23.50% | 9.20% |  |  |
UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,093 | $ 819 | 663 |  |
Percentage Change In Sales By Segment Of Business | 33.50% | 23.50% |  |  |
Other | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 416 | $ 476 | 695 |  |
Percentage Change In Sales By Segment Of Business | (12.80%) | (31.50%) |  |  |
Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,186 | $ 1,353 | 1,470 |  |
Percentage Change In Sales By Segment Of Business | (12.40%) | (8.00%) |  |  |
Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,345 | $ 2,313 | 2,477 |  |
Percentage Change In Sales By Segment Of Business | 1.40% | (6.60%) |  |  |
INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 795 | $ 735 | 881 |  |
Percentage Change In Sales By Segment Of Business | 8.20% | (16.50%) |  |  |
PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 552 | $ 790 | 988 |  |
Percentage Change In Sales By Segment Of Business | (30.20%) | (20.00%) |  |  |
HIPS | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,280 | $ 1,438 | 1,418 |  |
Percentage Change In Sales By Segment Of Business | (11.00%) | 1.40% |  |  |
KNEES | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,170 | $ 1,480 | 1,502 |  |
Percentage Change In Sales By Segment Of Business | (21.00%) | (1.40%) |  |  |
TRAUMA | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,614 | $ 2,720 | 2,699 |  |
Percentage Change In Sales By Segment Of Business | (3.90%) | 0.80% |  |  |
SPINE & OTHER | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,699 | $ 3,201 | 3,266 |  |
Percentage Change In Sales By Segment Of Business | (15.70%) | (2.00%) |  |  |
ADVANCED | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,839 | $ 4,095 | 4,002 |  |
Percentage Change In Sales By Segment Of Business | (6.20%) | 2.30% |  |  |
GENERAL | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,392 | $ 5,406 | 5,899 |  |
Percentage Change In Sales By Segment Of Business | (18.80%) | (8.40%) |  |  |
CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,994 | $ 3,392 | 3,302 |  |
Percentage Change In Sales By Segment Of Business | (11.70%) | 2.70% |  |  |
SURGICAL | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 925 | $ 1,232 | 1,251 |  |
Percentage Change In Sales By Segment Of Business | (24.90%) | (1.60%) |  |  |
Skin health/Beauty | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,450 | $ 4,593 | 4,382 |  |
Percentage Change In Sales By Segment Of Business | (3.10%) | 4.80% |  |  |
United States |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 43,133 | $ 42,097 | 41,884 |  |
Percentage Change In Sales By Segment Of Business | 2.50% | 0.50% |  |  |
United States | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 6,362 | $ 5,839 | 5,761 |  |
Percentage Change In Sales By Segment Of Business | 9.00% | 1.40% |  |  |
United States | Pharmaceutical |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 25,735 | $ 23,874 | 23,286 |  |
Percentage Change In Sales By Segment Of Business | 7.80% | 2.50% |  |  |
United States | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 10,175 | $ 9,641 | 9,073 |  |
Percentage Change In Sales By Segment Of Business | 5.50% | 6.30% |  |  |
United States | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,735 | $ 1,597 | 1,378 |  |
Percentage Change In Sales By Segment Of Business | 8.60% | 15.90% |  |  |
United States | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,091 | $ 2,919 | 2,574 |  |
Percentage Change In Sales By Segment Of Business | 5.90% | 13.40% |  |  |
United States | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 5,092 | $ 4,299 | 4,331 |  |
Percentage Change In Sales By Segment Of Business | 18.50% | (0.70%) |  |  |
United States | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,133 | $ 1,684 | 1,651 |  |
Percentage Change In Sales By Segment Of Business | 26.60% | 2.00% |  |  |
United States | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,509 | $ 3,734 | 4,279 |  |
Percentage Change In Sales By Segment Of Business | (6.00%) | (12.70%) |  |  |
United States | Pharmaceutical | OPSUMIT |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Segment Of Business |  | 9.40% |  |  |
United States | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 11,036 | $ 12,384 | 12,837 |  |
Percentage Change In Sales By Segment Of Business | (10.90%) | (3.50%) |  |  |
United States | Medical Devices | Diabetes Care |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers |  |  | 371 |  |
United States | Medical Devices | Interventional Solutions |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,452 | $ 1,443 | 1,283 |  |
Percentage Change In Sales By Segment Of Business | 0.60% | 12.50% |  |  |
United States | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,779 | $ 5,319 | 5,281 |  |
Percentage Change In Sales By Segment Of Business | (10.20%) | 0.70% |  |  |
United States | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,249 | $ 3,828 | 4,125 |  |
Percentage Change In Sales By Segment Of Business | (15.10%) | (7.20%) |  |  |
United States | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,557 | $ 1,794 | 1,777 |  |
Percentage Change In Sales By Segment Of Business | (13.20%) | 0.90% |  |  |
United States | Baby Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 376 | $ 362 | 422 |  |
Percentage Change In Sales By Segment Of Business | 3.70% | (14.20%) |  |  |
United States | Oral Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 683 | $ 621 | 637 |  |
Percentage Change In Sales By Segment Of Business | 9.90% | (2.50%) |  |  |
United States | OTC | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,460 | $ 2,010 | 1,850 |  |
Percentage Change In Sales By Segment Of Business | 22.40% | 8.60% |  |  |
United States | Women's Health | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 13 | $ 12 | 13 |  |
Percentage Change In Sales By Segment Of Business | 8.20% | (5.50%) |  |  |
United States | Wound Care and Other | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 480 | $ 441 | 436 |  |
Percentage Change In Sales By Segment Of Business | 8.90% | 1.20% |  |  |
United States | Remicade | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,508 | $ 3,079 | 3,664 |  |
Percentage Change In Sales By Segment Of Business | (18.50%) | (16.00%) |  |  |
United States | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,155 | $ 1,159 | 1,051 |  |
Percentage Change In Sales By Segment Of Business | (0.30%) | 10.20% |  |  |
United States | Stelara | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 5,240 | $ 4,346 | 3,469 |  |
Percentage Change In Sales By Segment Of Business | 20.60% | 25.30% |  |  |
United States | Tremfya | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 926 | $ 764 | 453 |  |
Percentage Change In Sales By Segment Of Business | 21.30% | 68.50% |  |  |
United States | Other Immunology | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 0 | $ 0 | 0 |  |
Percentage Change In Sales By Segment Of Business | 0.00% | 0.00% |  |  |
United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 44 | $ 50 | 58 |  |
Percentage Change In Sales By Segment Of Business | (11.20%) | (13.70%) |  |  |
United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,587 | $ 1,422 | 1,169 |  |
Percentage Change In Sales By Segment Of Business | 11.60% | 21.60% |  |  |
United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 104 | $ 126 | 151 |  |
Percentage Change In Sales By Segment Of Business | (17.60%) | (16.50%) |  |  |
United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 183 | $ 233 | 229 |  |
Percentage Change In Sales By Segment Of Business | (21.40%) | 1.70% |  |  |
United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,314 | $ 2,107 | 1,791 |  |
Percentage Change In Sales By Segment Of Business | 9.80% | 17.60% |  |  |
United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 296 | $ 314 | 315 |  |
Percentage Change In Sales By Segment Of Business | (5.90%) | (0.30%) |  |  |
United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 298 | $ 266 | 239 |  |
Percentage Change In Sales By Segment Of Business | 12.40% | 11.40% |  |  |
United States | DARZALEX | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,232 | $ 1,567 | 1,203 |  |
Percentage Change In Sales By Segment Of Business | 42.40% | 30.30% |  |  |
United States | Erleada | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 583 | $ 297 | 124 |  |
Percentage Change In Sales By Segment Of Business | 96.10% |  |  |  |
United States | IMBRUVICA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,821 | $ 1,555 | 1,129 |  |
Percentage Change In Sales By Segment Of Business | 17.10% | 37.70% |  |  |
United States | VELCADE | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 0 | $ 0 | 0 |  |
Percentage Change In Sales By Segment Of Business | 0.00% | 0.00% |  |  |
United States | ZYTIGA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 373 | $ 810 | 1,771 |  |
Percentage Change In Sales By Segment Of Business | (54.00%) | (54.30%) |  |  |
United States | Other Oncology | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 83 | $ 70 | 104 |  |
Percentage Change In Sales By Segment Of Business | 19.20% | (32.70%) |  |  |
United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,008 | $ 766 | 700 |  |
Percentage Change In Sales By Segment Of Business | 31.70% |  |  |  |
United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 955 | $ 714 | 598 |  |
Percentage Change In Sales By Segment Of Business | 33.80% | 19.30% |  |  |
United States | Other | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 169 | $ 205 | 353 |  |
Percentage Change In Sales By Segment Of Business | (17.60%) | (41.90%) |  |  |
United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 323 | $ 380 | 417 |  |
Percentage Change In Sales By Segment Of Business | (15.10%) | (9.10%) |  |  |
United States | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,345 | $ 2,313 | 2,477 |  |
Percentage Change In Sales By Segment Of Business | 1.40% | (6.60%) |  |  |
United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 564 | $ 536 | 711 |  |
Percentage Change In Sales By Segment Of Business | 5.20% | (24.60%) |  |  |
United States | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 277 | $ 505 | 674 |  |
Percentage Change In Sales By Segment Of Business | (45.10%) | (25.10%) |  |  |
United States | HIPS | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 793 | $ 863 | 841 |  |
Percentage Change In Sales By Segment Of Business | (8.20%) | 2.60% |  |  |
United States | KNEES | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 743 | $ 889 | 911 |  |
Percentage Change In Sales By Segment Of Business | (16.40%) | (2.40%) |  |  |
United States | TRAUMA | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,648 | $ 1,652 | 1,599 |  |
Percentage Change In Sales By Segment Of Business | (0.20%) | 3.30% |  |  |
United States | SPINE & OTHER | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,595 | $ 1,915 | 1,930 |  |
Percentage Change In Sales By Segment Of Business | (16.70%) | (0.80%) |  |  |
United States | ADVANCED | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,535 | $ 1,637 | 1,657 |  |
Percentage Change In Sales By Segment Of Business | (6.20%) | (1.20%) |  |  |
United States | GENERAL | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,714 | $ 2,192 | 2,468 |  |
Percentage Change In Sales By Segment Of Business | (21.80%) | (11.20%) |  |  |
United States | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,213 | $ 1,304 | 1,237 |  |
Percentage Change In Sales By Segment Of Business | (7.00%) | 5.40% |  |  |
United States | SURGICAL | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 344 | $ 490 | 540 |  |
Percentage Change In Sales By Segment Of Business | (29.70%) | (9.40%) |  |  |
United States | Skin health/Beauty | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,350 | $ 2,392 | 2,403 |  |
Percentage Change In Sales By Segment Of Business | (1.70%) | (0.40%) |  |  |
Non-US |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 39,451 | $ 39,962 | 39,697 |  |
Percentage Change In Sales By Segment Of Business | (1.30%) | 0.70% |  |  |
Non-US | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 7,691 | $ 8,059 | 8,092 |  |
Percentage Change In Sales By Segment Of Business | (4.60%) | (0.40%) |  |  |
Non-US | Pharmaceutical |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 19,837 | $ 18,324 | 17,448 |  |
Percentage Change In Sales By Segment Of Business | 8.30% | 5.00% |  |  |
Non-US | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,880 | $ 4,309 | 4,047 |  |
Percentage Change In Sales By Segment Of Business | 13.20% | 6.50% |  |  |
Non-US | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,839 | $ 1,815 | 1,926 |  |
Percentage Change In Sales By Segment Of Business | 1.30% | (5.70%) |  |  |
Non-US | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 3,457 | $ 3,409 | 3,503 |  |
Percentage Change In Sales By Segment Of Business | 1.40% | (2.70%) |  |  |
Non-US | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 7,275 | $ 6,393 | 5,513 |  |
Percentage Change In Sales By Segment Of Business | 13.80% | 16.00% |  |  |
Non-US | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,015 | $ 939 | 922 |  |
Percentage Change In Sales By Segment Of Business | 8.20% | 1.90% |  |  |
Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,369 | $ 1,458 | 1,537 |  |
Percentage Change In Sales By Segment Of Business | (6.10%) | (5.20%) |  |  |
Non-US | Pharmaceutical | OPSUMIT |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Percentage Change In Sales By Segment Of Business |  | 9.00% |  |  |
Non-US | Medical Devices |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 11,923 | $ 13,579 | 14,157 |  |
Percentage Change In Sales By Segment Of Business | (12.20%) | (4.10%) |  |  |
Non-US | Medical Devices | Diabetes Care |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers |  |  | 638 |  |
Non-US | Medical Devices | Interventional Solutions |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,594 | $ 1,554 | 1,363 |  |
Percentage Change In Sales By Segment Of Business | 2.60% | 14.00% |  |  |
Non-US | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,984 | $ 3,520 | 3,604 |  |
Percentage Change In Sales By Segment Of Business | (15.20%) | (2.30%) |  |  |
Non-US | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 4,983 | $ 5,673 | 5,776 |  |
Percentage Change In Sales By Segment Of Business | (12.20%) | (1.80%) |  |  |
Non-US | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,362 | $ 2,830 | 2,776 |  |
Percentage Change In Sales By Segment Of Business | (16.50%) | 2.00% |  |  |
Non-US | Baby Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,141 | $ 1,313 | 1,436 |  |
Percentage Change In Sales By Segment Of Business | (13.10%) | (8.60%) |  |  |
Non-US | Oral Care | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 958 | $ 906 | 918 |  |
Percentage Change In Sales By Segment Of Business | 5.70% | (1.20%) |  |  |
Non-US | OTC | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,364 | $ 2,434 | 2,484 |  |
Percentage Change In Sales By Segment Of Business | (2.90%) | (2.00%) |  |  |
Non-US | Women's Health | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 888 | $ 974 | 1,036 |  |
Percentage Change In Sales By Segment Of Business | (8.80%) | (6.00%) |  |  |
Non-US | Wound Care and Other | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 240 | $ 230 | 239 |  |
Percentage Change In Sales By Segment Of Business | 4.10% | (3.90%) |  |  |
Non-US | Remicade | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 893 | $ 1,007 | 1,226 |  |
Percentage Change In Sales By Segment Of Business | (11.40%) | (17.80%) |  |  |
Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,088 | $ 1,029 | 1,033 |  |
Percentage Change In Sales By Segment Of Business | 5.80% | (0.40%) |  |  |
Non-US | Stelara | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,467 | $ 2,015 | 1,687 |  |
Percentage Change In Sales By Segment Of Business | 22.40% | 19.40% |  |  |
Non-US | Tremfya | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 421 | $ 248 | 91 |  |
Percentage Change In Sales By Segment Of Business | 69.90% |  |  |  |
Non-US | Other Immunology | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 11 | $ 10 | 10 |  |
Percentage Change In Sales By Segment Of Business | 6.40% | 4.50% |  |  |
Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 920 | $ 812 | 758 |  |
Percentage Change In Sales By Segment Of Business | 13.30% | 7.10% |  |  |
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 597 | $ 689 | 786 |  |
Percentage Change In Sales By Segment Of Business | (13.40%) | (12.30%) |  |  |
Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 323 | $ 315 | 382 |  |
Percentage Change In Sales By Segment Of Business | 2.60% | (17.60%) |  |  |
Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 439 | $ 463 | 434 |  |
Percentage Change In Sales By Segment Of Business | (5.10%) | 6.60% |  |  |
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,339 | $ 1,224 | 1,137 |  |
Percentage Change In Sales By Segment Of Business | 9.40% | 7.70% |  |  |
Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 346 | $ 374 | 422 |  |
Percentage Change In Sales By Segment Of Business | (7.50%) | (11.40%) |  |  |
Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,334 | $ 1,349 | 1,510 |  |
Percentage Change In Sales By Segment Of Business | (1.10%) | (10.70%) |  |  |
Non-US | DARZALEX | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,958 | $ 1,430 | 822 |  |
Percentage Change In Sales By Segment Of Business | 36.90% | 73.90% |  |  |
Non-US | Erleada | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 176 | $ 35 | 0 |  |
Non-US | IMBRUVICA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,307 | $ 1,856 | 1,486 |  |
Percentage Change In Sales By Segment Of Business | 24.30% | 24.90% |  |  |
Non-US | VELCADE | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 408 | $ 751 | 1,116 |  |
Percentage Change In Sales By Segment Of Business | (45.70%) | (32.70%) |  |  |
Non-US | ZYTIGA | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,097 | $ 1,985 | 1,727 |  |
Percentage Change In Sales By Segment Of Business | 5.60% | 15.00% |  |  |
Non-US | Other Oncology | Pharmaceutical | Oncology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 330 | $ 336 | 362 |  |
Percentage Change In Sales By Segment Of Business | (1.90%) | (7.20%) |  |  |
Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 631 | $ 562 | 515 |  |
Percentage Change In Sales By Segment Of Business | 12.30% |  |  |  |
Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 138 | $ 105 | 65 |  |
Percentage Change In Sales By Segment Of Business | 30.90% | 62.40% |  |  |
Non-US | Other | Pharmaceutical | Pulmonary Hypertension |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 247 | $ 272 | 342 |  |
Percentage Change In Sales By Segment Of Business | (9.20%) | (20.50%) |  |  |
Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 864 | $ 974 | 1,053 |  |
Percentage Change In Sales By Segment Of Business | (11.30%) | (7.60%) |  |  |
Non-US | Xarelto | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 0 | $ 0 | 0 |  |
Percentage Change In Sales By Segment Of Business | 0.00% | 0.00% |  |  |
Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 231 | $ 199 | 170 |  |
Percentage Change In Sales By Segment Of Business | 16.30% | 17.30% |  |  |
Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 274 | $ 285 | 314 |  |
Percentage Change In Sales By Segment Of Business | (3.80%) | (9.20%) |  |  |
Non-US | HIPS | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 487 | $ 575 | 577 |  |
Percentage Change In Sales By Segment Of Business | (15.30%) | (0.30%) |  |  |
Non-US | KNEES | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 427 | $ 591 | 591 |  |
Percentage Change In Sales By Segment Of Business | (27.80%) | 0.00% |  |  |
Non-US | TRAUMA | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 966 | $ 1,068 | 1,100 |  |
Percentage Change In Sales By Segment Of Business | (9.60%) | (2.90%) |  |  |
Non-US | SPINE & OTHER | Medical Devices | Orthopaedics |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,104 | $ 1,286 | 1,336 |  |
Percentage Change In Sales By Segment Of Business | (14.10%) | (3.80%) |  |  |
Non-US | ADVANCED | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,304 | $ 2,458 | 2,345 |  |
Percentage Change In Sales By Segment Of Business | (6.20%) | 4.80% |  |  |
Non-US | GENERAL | Medical Devices | Surgery |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,679 | $ 3,215 | 3,431 |  |
Percentage Change In Sales By Segment Of Business | (16.70%) | (6.30%) |  |  |
Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 1,781 | $ 2,088 | 2,065 |  |
Percentage Change In Sales By Segment Of Business | (14.70%) | 1.10% |  |  |
Non-US | SURGICAL | Medical Devices | Vision |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 581 | $ 742 | 711 |  |
Percentage Change In Sales By Segment Of Business | (21.70%) | 4.40% |  |  |
Non-US | Skin health/Beauty | Consumer |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 2,100 | $ 2,201 | 1,979 |  |
Percentage Change In Sales By Segment Of Business | (4.60%) | 11.20% |  |  |
UNITED STATES Exports | Remicade | Pharmaceutical | Immunology |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Sales to Customers | $ 346 | $ 294 | $ 436 |  |
Percentage Change In Sales By Segment Of Business | 18.00% | (32.70%) |  |  |
Auris Health | Pharmaceutical |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Business Combination, Acquisition Related Costs |  | $ 100 |  |  |
Pending Litigation |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |
Loss contingency, estimate of possible loss |  |  |  | $ 5,000 | $ 4,000

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248 + Details
Name: | us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ErleadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |